Assessment and comparison of prognostic classification schemes for survival data

…, C Schmoor, W Sauerbrei, M Schumacher - Statistics in …, 1999 - Wiley Online Library
Prognostic classification schemes have often been used in medical applications, but rarely
subjected to a rigorous examination of their adequacy. For survival data, the statistical …

[BOOK][B] Competing risks and multistate models with R

J Beyersmann, A Allignol, M Schumacher - 2011 - books.google.com
This book covers competing risks and multistate models, sometimes summarized as event
history analysis. These models generalize the analysis of time to a single event (survival …

Simulating competing risks data in survival analysis

…, A Latouche, A Buchholz, M Schumacher - Statistics in …, 2009 - Wiley Online Library
Competing risks analysis considers time‐to‐first‐event (‘survival time’) and the event type (‘cause’),
possibly subject to right‐censoring. The cause‐, ie event‐specific hazards, …

On pseudo-values for regression analysis in competing risks models

F Graw, TA Gerds, M Schumacher - Lifetime data analysis, 2009 - Springer
For regression on state and transition probabilities in multi-state models Andersen et al. (Biometrika
90:15–27, 2003) propose a technique based on jackknife pseudo-values. In this …

[HTML][HTML] Undue reliance on I 2 in assessing heterogeneity may mislead

…, G Schwarzer, JR Carpenter, M Schumacher - BMC medical research …, 2008 - Springer
Background The heterogeneity statistic I 2 , interpreted as the percentage of variability due
to heterogeneity between studies rather than sampling error, depends on precision, that is, …

Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials

…, V Moebus, G Thomas, M Untch, M Schumacher… - The Lancet, 2009 - thelancet.com
Background Erythropoiesis-stimulating agents reduce anaemia in patients with cancer and
could improve their quality of life, but these drugs might increase mortality. We therefore did a …

A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs

…, A Sidoroff, C De Toma, M Schumacher… - Pharmacogenetics …, 2008 - journals.lww.com
Background Stevens–Johnson syndrome (SJS) and its severe form, toxic epidermal necrolysis
(TEN), are rare but life-threatening cutaneous adverse reactions to drugs, especially to …

A bootstrap resampling procedure for model building: application to the Cox regression model

W Sauerbrei, M Schumacher - Statistics in medicine, 1992 - Wiley Online Library
A common problem in the statistical analysis of clinical studies is the selection of those
variables in the framework of a regression model which might influence the outcome variable. …

How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial

…, C Wanner, E Ferrannini, M Schumacher… - Diabetes …, 2018 - Am Diabetes Assoc
OBJECTIVE In the BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2
Diabetes Mellitus Patients (EMPA-REG OUTCOME) trial involving 7,020 patients with type 2 …

Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: a cohort study

…, U Frank, K Mertens, M Schumacher… - The Lancet infectious …, 2011 - thelancet.com
Background Patients admitted to intensive-care units are at high risk of health-care-associated
infections, and many are caused by antimicrobial-resistant pathogens. We aimed to …